On the other hand, after comparing two therapies (anthracycline-containing chemotherapy and anthracycline-free chemotherapy), Schramm et al. [77] did not notice any differences in the number of CTCs between the therapies in the HER2-negative patients with early BC included in SUCCESS C study. Here, ERBB2 is linked to breast cancer.